Evolución clínica de la uveítis intermedia asociada a infección por el virus linfotrópico de células T humano tipo 1 (HTLV-1) / Clinical course of HTLV-1 infection associated intermediate uveitis

Objetivo: Describir las características asociadas a la presentación, tratamiento y seguimiento de una serie de casos de uveítis intermedia asociada al virus linfotrópico de células T humano de tipo 1 (HTLV-1).Pacientes y métodosEstudio retrospectivo, descriptivo y longitudinal. Se incluyó a pacientes con uveítis intermedia asociada a infección por HTLV-1 atendidos en una clínica oftalmológica de referencia de Lima (Perú), durante 2012-2018.ResultadosSe incluyó a 18 pacientes (28 ojos). La edad promedio a la presentación fue de 57,3 años; el 66,6% fueron mujeres. El tiempo de seguimiento promedio fue de 1.280 días. Los síntomas más frecuentes fueron visión borrosa o disminuida (78,6%) y visión de cuerpos flotantes (57,1%). La agudeza visual mejor corregida fue de 20/40 o mejor en el 53,6%. La presión intraocular inicial promedio fue de 14,95mmHg. Se observaron precipitados retroqueráticos en el 50% de ojos, siendo el tipo más frecuente el espiculado (17,9% de los ojos). El tratamiento más frecuente fue la inyección periocular de corticoides (en el 53,6% de los ojos). Se presentaron complicaciones como membrana epimacular (50%), catarata (21,4%) y glaucoma (7,1%). Al final del seguimiento, solo 2 ojos perdieron una línea de visión; la agudeza visual mejor corregida final fue de 20/40 o mejor en el 85,7%, y de 20/70 o mejor en el 96,4%. Los pacientes afectados en ambos ojos aumentaron de 33% a la presentación a 55,5%. El curso de la enfermedad fue crónico en el 60,7%.ConclusiónLa uveítis intermedia asociada a infección por HTLV-1 se presentó principalmente en la segunda mitad de la vida, con curso crónico y buen pronóstico visual. (AU)

Objective: To describe the clinical features at presentation, delivered treatment and follow-up of a case series of human T-cell lymphotropic virus type 1 (HTLV-1) associated intermediate uveitis.Patients and methodsRetrospective, descriptive and longitudinal study of patients with HTLV-1 associated intermediate uveitis treated at a reference ophthalmology facility in Lima, Peru, during the years 2012 to 2018.ResultsA total of 18 patients (28 eyes) were included, the average age at presentation was 57.3 years, 66.6% were women, and the average follow-up time was 1,280 days. The most frequent symptoms were blurred or diminished vision (78.6%) and floaters (57.1%). Best corrected visual acuity was 20/40 or better in 53.6%. The mean initial intraocular pressure was 14.95mmHg. Keratic precipitates were observed in 50% of eyes, 17.9% were of the stellate type. The most frequent treatment was periocular corticosteroid injections (53.6%). Complications such as epimacular membrane (50%), cataract (21.4%) and glaucoma (7.1%) occurred. At the end of follow-up, only 2 eyes lost one line of vision; the final best corrected visual acuity was 20/40 or better in 85.7%, and 20/70 or better in 96.4%. Patients with both eyes affected increased from 33% at presentation to 55.5%. The course of the disease was chronic in 60.7%.ConclusionHTLV-1 associated intermediate uveitis mainly occurred in patients in the second half of life, developing a chronic course and with good visual prognosis. (AU)

Chikungunya Virus Infection Manifesting as Intermediate Uveitis.

PURPOSE: To describe a case of intermediate uveitis caused by chikungunya virus infection in the Western Hemisphere. METHODS: Case report of a patient diagnosed with chikungunya infection presenting with blurry vision and floaters. RESULTS: Exam revealed a unilateral intermediate uveitis, with an extensive work-up positive for chikungunya virus immunoglobulin M and G titers. The patient responded to oral corticosteroids with signs and symptoms resolving over the course of 3 months' treatment. CONCLUSIONS: While anterior uveitis and retinitis are the most common ocular manifestations of chikungunya infection, we report here a case of chikungunya infection presenting as an intermediate uveitis, responding well to oral corticosteroids. This case demonstrates the varied presentation of chikungunya-related uveitis and highlights its consideration in the differential diagnoses of those who have had preceding systemic viral symptoms and uveitis.

Intermediate uveitis: an unusual presentation of cytomegalovirus intraocular infection in an immunocompetent patient.

We report a case of cytomegalovirus (CMV) intraocular infection in an otherwise healthy 51-year-old patient, presenting atypically as isolated intermediate uveitis without retinitis or retinal vasculitis. The patient had a confirmed CMV infection as a cause of her intraocular inflammation via PCR DNA testing of an aqueous sample. Appropriate oral antiviral therapy was initiated, and resulted in complete resolution of inflammation and improvement in visual acuity. Prophylactic therapy was instituted thereafter.

[Intermediate uveitis due to human T-cell lymphotropic virus type 1]. / Uveítis intermedia por virus linfotropo humano de células T Tipo 1.

CASE REPORT: The case of a 66-year-old woman with intermediate uveitis in both eyes and progressive weakness of lower limbs is reported. A human T-lymphotropic virus type 1 (HTLV-1) infection was detected in the serological study, with the patient being diagnosed with tropical spastic paraparesis and HTLV-1 intermediate uveitis. The patient made good progress with oral steroid treatment. DISCUSSION: The clinical and epidemiological aspects of HTLV-1 infection are discussed. We recommend a serological determination of the virus in intermediate uveitis of unknown origin in people from endemic areas or with neurological symptoms.

Rubella-related intermediate uveitis in pregnancy--a rare presentation.

PURPOSE: To report a rare case of intermediate uveitis following rubella infection in pregnancy. DESIGN: Case report. METHODS: A 35-year-old pregnant woman, at 24 weeks of gestation, presented with sudden floaters and blurring of vision of the left eye. Ocular examination revealed vitritis 1-2+ with no retinal involvement. Rubella serology showed a high IgG titr eof 268 IU/mL. Treatment with periocular steroids (posterior subtenon triamcinalone) injection into the left eye was initiated. RESULTS: Improvement of vision with resolution of the vitritis was seen after 3 weeks. Repeat rubella IgG titer dropped to 20.4 IU/mL. Obstetrics evaluation of the fetus remained normal. CONCLUSIONS: Rubella-related intermediate uveitis is a very rare presentation during pregnancy. It is worthwhile to investigate for rubella infections in pregnant patients complaining of recent onset of visual disturbances. This type of intermediate uveitis can be treated successfully with minimal ocular complications if recognized early.

Uveitis in children with human immunodeficiency virus-associated arthritis.

PURPOSE: To describe the ocular inflammatory manifestations and clinical characteristics of children with Human Immunodeficiency Virus (HIV)-associated arthritis. METHODS: A retrospective review of the charts of children with chronic uveitis and HIV-associated arthritis seen between June 2004 and September 2006 at Inkosi Albert Luthuli Central Hospital, Durban, South Africa. The following data were analyzed: age at presentation, gender, race/ethnicity, rheumatologic problems, uveitic diagnosis, laboratory findings, and ocular complications. RESULTS: Seven black African males with a mean age of 9 years (range, 4 to 13 years) were identified. There were no other significant laboratory findings apart from HIV; all patients were antinuclear antibody negative. Arthritis was polyarticular in 6 patients and pauciarticular in 1. Four patients had intermediate uveitis and 3 patients had nongranulomatous anterior uveitis. Visual acuity ranged from 20/20 to hand movements. Ocular complications included cataract, cystoid macular edema, hypotony, pupillary membranes, band keratopathy, posterior synechiae and optic disk edema. CONCLUSIONS: HIV-associated arthritis and uveitis in children is a clinical syndrome that may be associated with severe sight-threatening intraocular inflammation. Routine eye screening in HIV-positive children, particularly those with arthritis, is warranted to facilitate prompt treatment.